<div id="readability-page-1"><p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) shares traded down 9.2% during trading on Monday . The company traded as low as $33.63 and last traded at $33.4240. 255,118 shares changed hands during mid-day trading, an increase of 21% from the average session volume of 210,240 shares. The stock had previously closed at $36.80.</p><div><p><span></span><span>Get <strong>Rapt Therapeutics</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>A number of equities research analysts have recently issued reports on the stock. Barclays dropped their target price on shares of Rapt Therapeutics from $58.00 to $56.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, November 7th. Zacks Research lowered Rapt Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, August 22nd. Leerink Partners raised shares of Rapt Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and raised their target price for the stock from $16.00 to $37.00 in a report on Friday, September 26th. Leerink Partnrs raised Rapt Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, September 25th. Finally, Wells Fargo &amp; Company  set a $72.00 target price on Rapt Therapeutics and gave the company an &#34;overweight&#34; rating in a report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $50.50.</p><p><b>Read Our Latest Stock Report on Rapt Therapeutics</b></p><h2>Rapt Therapeutics Stock Down 9.7%</h2><p>The stock's 50-day simple moving average is $30.39 and its 200 day simple moving average is $18.69. The firm has a market cap of $920.53 million, a P/E ratio of -3.00 and a beta of 0.43. </p><p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.23.  On average, research analysts forecast that  Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. raised its holdings in shares of  Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company's stock valued at $72,000 after purchasing an additional 47,391 shares during the period.  Comerica Bank grew its stake in shares of  Rapt Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares during the period.  Checkpoint Capital L.P. bought a new stake in  Rapt Therapeutics in the 1st quarter valued at about $134,000.  Nuveen LLC bought a new stake in  Rapt Therapeutics in the 1st quarter valued at about $143,000.  Finally, Charles Schwab Investment Management Inc. raised its stake in  Rapt Therapeutics by 112.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 150,946 shares of the company's stock worth $184,000 after buying an additional 79,967 shares during the period. 99.09% of the stock is owned by institutional investors. </p><h2>About Rapt Therapeutics</h2> (Get Free Report)<p>RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Rapt Therapeutics</li><li>How to Plot Fibonacci Price Inflection Levels </li><li>Is Nutanix the Best Comeback Trade Left in 2025? The Setup Says Yes</li><li>How to trade penny stocks: A step-by-step guide</li><li>The Vertiv Pullback: Ignore the Noise, Buy the Data</li><li>How to Capture the Benefits of Dividend Increases</li><li>Insiders Buy Natural Gas Stocks: 2 for the Watchlist</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Rapt Therapeutics Right Now?</h2><p>Before you consider Rapt Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.</p><p>While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RAPT

<p>Rapt Therapeutics (NASDAQ:RAPT) shares fell 9.2% on Monday, trading as low as $33.63. Despite the drop, analysts have mixed ratings: Barclays set a target price of $56, Zacks downgraded to 'hold', while Leerink Partners upgraded to 'outperform' with a $37 target. The stock has a consensus 'Moderate Buy' rating with a $50.50 target. Institutional investors hold 99.09% of shares. Rapt focuses on developing therapies for oncology and inflammatory diseases.</p>

Rapt Therapeutics (NASDAQ:RAPT) Stock Price Down 9.2% - Should You Sell?